Bronchial inflammation is a key feature of asthma since mediators released by inflammatory cells may induce acute damages and structural changes to the airways. Airway inflammation is, therefore, a primary therapeutic goal and that treatment with anti-inflammatory drugs should be started as early as possible, when needed. The need to monitor inflammation has led to the exploration of exhaled gases. In the last years, several reports have demonstrated that increased nitric oxide (NO) is present in the expired air of patients with asthma and that measurement of the fractional concentration of exhaled NO (FENO) may represents a non invasive, simple, well tolerated test thought to reflect the airway inflammatory events in asthmatic patients.
|Number of pages||7|
|Journal||Allergy and Clinical Immunology International|
|Publication status||Published - Jan 2003|
ASJC Scopus subject areas
- Immunology and Allergy